Britain’s biggest drugmaker acquires Seattle-based firm Icosavax, expanding vaccine and immune therapy business
AstraZeneca is buying its first vaccine company in a $1.1bn deal that will expand the vaccine and immune therapy business it set up during the Covid pandemic.
Britain’s biggest drugmaker has agreed to take over the Seattle-based company Icosavax, which is developing a potential vaccine for two common respiratory diseases.
More Stories
Cancer experts warn of coffee enemas and juice diets amid rise in misinformation
Elon Musk shows he still has the White House’s ear on Trump’s Middle East trip
Poorer children more likely to age faster than affluent counterparts, study finds